| 货号 | AB-278-NA |
| 别名 | chemokine (C-C motif) ligand 5; D17S136Enormally T-expressed, and presumably secreted; EoCP; Eosinophil chemotactic cytokine; RANTES; SISd; SIS-delta; small inducible cytokine A5 (RANTES); small inducible cytokine subfamily A (Cys-Cys), member 5; Small-inducible cytokine A5; T cell-specific protein P228; T-cell specific protein p288; TCP228T-cell-specific protein RANTES |
| 反应种属 | Human |
| 应用 | Western Blot(1 µg/mL) |
| 目标/特异性 | Detects human CCL5/RANTES in direct ELISAs and Western blots. In direct ELISAs, less than 10% cross-reactivity with recombinant mouse C10 is observed. |
| 使用方法 | Western Blot: 1 µg/mL Neutralization: Measured by its ability to neutralize CCL5/RANTES-induced chemotaxis in human monocytes. The Neutralization Dose (ND50) is typically 10-30 µg/mL in the presence of 0.2 µg/mL Recombinant Human CCL5/RANTES. |
| 来源 | Polyclonal Goat IgG |
| 产品组分 |
| 供应商 | R&D Systems |
| Entrez Gene IDs | 6352 (Human); 20304 (Mouse); 403522 (Canine); 493689 (Feline) |
| 应用文献 | |
| R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions. Up-regulation of platelet activation in hemophilia A. | |
| 纯化方式 | Protein A or G purified |
| 免疫原 | E. coli-derived recombinant human CCL5/RANTES Ser25-Ser91 Accession # P13501 |
| 内毒素水平 | <0.10 EU per 1 μg of the antibody by the LAL method. |
| 生物活性 | Human |
| 标记 | Unconjugated |
| 溶解方法 | Reconstitute at 1 mg/mL in sterile PBS. |
| 背景 | CCL5, also known as RANTES (Regulated upon Activation, Normal T cell Expressed and presumably Secreted), is an 8 kDa beta ‑chemokine that plays a primary role in the inflammatory immune response by means of its ability to attract and activate leukocytes (1‑3). Human and mouse RANTES exhibit cross-species activity on human and mouse cells (4). Mature human CCL5 shares 75%‑84% aa seqeuence identity with canine, cotton rat, feline, mouse, and rat CCL5 (5). CCL5 is secreted by many cell types at inflammatory sites, and it exerts a wide range of activities through the receptors CCR1, CCR3, CCR4, and CCR5 (6, 7). Inflammatory responses can be impaired by the sequestration of CCL5 by the cytomegalovirus protein US28 (8). In humans, CCR5 binding to CCL5 inhibits the infectivity of R5 (M-tropic) but not X4 (T-tropic) strains of HIV-1 (9). The two N-terminal residues of CCL5 can be removed by CD26/DPPIV, generating a protein that functions as a chemotaxis inhibitor and more effectively blocks M-tropic HIV-1 infection of monocytes (10). Oligomerization of CCL5 on glycosaminoglycans is required for CCR1‑mediated leukocyte adhesion and activation as well as CCL5’s interaction with the chemokine CXCL4/PF4 (11‑13). The deposition of CCL5 on activated vascular endothelial cells is crucial for monocyte adhesion to damaged vasculature, but CCL5 oligomerization is not required for the extravasation of adherent leukocytes (14‑16). CCL5 is upregulated in breast cancer and promotes tumor progression through the attraction of proinflammatory macrophages in addition to its actions on tumor cells, stromal cells, and the vasculature (17). |
| 运输条件 | Blue Ice |
| 存放说明 | -20℃ |
| 参考文献 |
|
Chemotaxis Induced by CCL5/RANTES and Neutralization by Human CCL5/RANTES Antibody. Recombinant Human CCL5/ |
